T 1500 rpm for 6 min at 4 , washed twice with 2 mL PBS + 2 BSA, and resuspended in 50 of PBS + 2 BSA solution for blocking. Antibodies were added to corresponding tubes and incubated in the dark at 4 for 45 min. Cells were removed from incubation, washed again twice with PBS + 2 BSA, and resuspended in PBS containing 0.5 formaldehyde. Cell populations were gated on a minimum of 250,000 ce
T 1500 rpm for 6 min at 4 , washed twice with 2 mL PBS + 2 BSA, and resuspended in 50 of PBS + 2 BSA solution for blocking. Antibodies were added to corresponding tubes and incubated in the dark at 4 for 45 min. Cells were removed from incubation, washed again twice with PBS + 2 BSA, and resuspended in PBS containing 0.5 formaldehyde. Cell populations were gated on a minimum of 250,000 ce
Erto Rico, School of Medicine, Pediatric HIV/AIDS Program. We also thank Linda Lambrecht, Robin Brody, James Coderre, Erik Larson, and Bruce Blais for technical support; Richard Konz, Jr., Director of the UMMS Flow Cytometry Core facility; Jeffrey Lifson, MD for reagents; Mario Roederer, PhD for providing SPICE; and Elizabeth Sheeran, MS, RD for protocol support. Source(s) of Support: Protocol dev
Ly at doses of 5 ?108 pfu each. Clinical monitoring for symptoms took place for one hour, and symptom diaries were kept for one week following each immunization. All toxicities noted during the study were classified by the DAIDS Toxicity Table for Grading Severity of Adult Adverse Experiences? dated August, 1992, and a protocol specific Supplemental Toxicity Table for reactogenicity occurring with
Nclusion criteria included: plasma HIV RNA levels (plasma viral load) 350 cells/mm3; and clinically healthy with all laboratory values grade
Nclusion criteria included: plasma HIV RNA levels (plasma viral load) 350 cells/mm3; and clinically healthy with all laboratory values grade
Nclusion criteria included: plasma HIV RNA levels (plasma viral load) 350 cells/mm3; and clinically healthy with all laboratory values grade
Lar haplotype assays (BioTest ABC SSPtray; BioTest Diagnostics Corp, Denville, NJ). Vaccinia-specific CD8 T-cell IFN and MIP-1 production was by flow cytometry measured using stimulation with live vaccinia virus (NYCBH strain) at an MOI of 5 as described by Precopio et al [18]. ELISPOT assays were performed utilizing MabtechTM ELISpot plus Human Interferon-gamma kits (MABTECH AB, Sweden). Cryopres